Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Stephen J. Freedland, Xuehua Ke, Marie-Hélène Lafeuille, Hela Romdhani, Frederic Kinkead, Patrick Lefebvre, Allison Petrilla, Zul Pulungan, Seung Kim, Denise M. D’Andrea, Peter Francis & Charles J. Ryan. (2021) Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. Current Medical Research and Opinion 37:4, pages 609-622.
Read now
Read now
Bingcao Wu, Sophia S. Li, Ji Song, Christopher D. Pericone, Ajay S. Behl & Nancy A. Dawson. (2020) Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. Journal of Medical Economics 23:1, pages 54-63.
Read now
Read now
Jinan Liu, Aimee Near, Joseph A. Chiarappa, Keiko Wada, Jenny Tse, Chakkarin Burudpakdee, Ajay Behl, Radhika Ranganath & Emmanuel S. Antonarakis. (2019) Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. Journal of Medical Economics 22:10, pages 1080-1087.
Read now
Read now
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka & Kentaro Enjo. (2018) Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. Current Medical Research and Opinion 34:10, pages 1855-1860.
Read now
Read now
A. Armstrong, C. Bui, K. Fitch, T. Goss Sawhney, B. Brown, S. Flanders, M. Balk, J. Deangelis & J. Chambers. (2017) Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current Medical Research and Opinion 33:6, pages 1133-1139.
Read now
Read now
Saku Torvinen, Niilo Färkkilä, Risto P. Roine, Harri Sintonen, Tiina Saarto & Kimmo Taari. (2016) Costs in different states of prostate cancer. Acta Oncologica 55:1, pages 30-37.
Read now
Read now
Articles from other publishers (9)
P. H. Dufton, M. F. Gerdtz, R. Jarden & M. Krishnasamy. (2022) Methodological approaches to measuring the incidence of unplanned emergency department presentations by cancer patients receiving systemic anti-cancer therapy: a systematic review. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Renske M.T. ten Ham, Merel van Nuland, Rick A. Vreman, Laurens G. de Graaf, Hilde Rosing, André M. Bergman, Alwin D.R. Huitema, Jos H. Beijnen & Anke M. Hövels. (2021) Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health 24:1, pages 121-128.
Crossref
Crossref
Michaela A. Dinan, Gary H. Lyman, Richard L. Schilsky & Daniel F. Hayes. (2019) Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology:3, pages 1-10.
Crossref
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Crossref
D. Cella, S. Traina, T. Li, K. Johnson, K.F. Ho, A. Molina & N.D. Shore. (2018) Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Annals of Oncology 29:2, pages 392-397.
Crossref
Crossref
Jan Norum & Carsten Nieder. (2017) Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. PharmacoEconomics 35:12, pages 1223-1236.
Crossref
Crossref
Kyle FlanneryEd DreaLouis HudspethShelby CormanXin GaoMei XueRaymond Miao. (2017) Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. Journal of Managed Care & Specialty Pharmacy 23:4, pages 416-426.
Crossref
Crossref
Keith L. Davis, Benjamin Gutierrez, Teresa Zyczynski & James A. Kaye. (2015) Real-World Treatment Patterns in Men with Castration-Resistant Prostate Cancer Receiving Docetaxel. Journal of Health Economics and Outcomes Research 2:2, pages 119-130.
Crossref
Crossref
Alice Dragomir, Daniela Dinea, Marie Vanhuyse, Fabio L Cury & Armen G Aprikian. (2014) Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Services Research 14:1.
Crossref
Crossref